-
公开(公告)号:US08575160B2
公开(公告)日:2013-11-05
申请号:US13511581
申请日:2010-11-29
申请人: Robert Sun , Lauren G. Monovich , Sylvie Chamoin , John Westbrook
发明人: Robert Sun , Lauren G. Monovich , Sylvie Chamoin , John Westbrook
IPC分类号: C07D487/04 , A61K31/4188 , A61K31/428
CPC分类号: C07D487/04 , C07D471/04
摘要: The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R7 and p are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式(I)化合物或其药学上可接受的盐,其中变量R1,R2,R3,R4,R5,R7和p在本文中定义。 本发明还涉及制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号:US20130065893A1
公开(公告)日:2013-03-14
申请号:US13511581
申请日:2010-11-29
申请人: Robert Sun , Lauren G. Monovich , Sylvie Chamoin , John Westbrook
发明人: Robert Sun , Lauren G. Monovich , Sylvie Chamoin , John Westbrook
IPC分类号: C07D487/04 , A61K31/4188 , A61K31/428 , A61K31/437 , A61K31/5377 , A61K31/4439 , A61K31/4725 , A61K31/4709 , A61P9/12 , A61P9/10 , A61P3/04 , A61P9/00 , A61P9/06 , A61P9/04 , A61P1/16 , C07D471/04
CPC分类号: C07D487/04 , C07D471/04
摘要: The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R7 and p are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式(I)化合物或其药学上可接受的盐,其中变量R1,R2,R3,R4,R5,R7和p在本文中定义。 本发明还涉及制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
3.
公开(公告)号:US08394853B2
公开(公告)日:2013-03-12
申请号:US12788766
申请日:2010-05-27
申请人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
发明人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
IPC分类号: A61K31/235 , C07C229/34
CPC分类号: C07D317/34 , A61K31/197 , A61K31/216 , A61K31/325 , A61K31/351 , A61K31/357 , A61K31/41 , A61K31/421 , A61K31/44 , A61K31/505 , A61K31/5375 , A61K45/00 , A61K45/06 , C07B2200/05 , C07C233/47 , C07C233/49 , C07C233/51 , C07C233/56 , C07C233/63 , C07C235/12 , C07C235/78 , C07C237/16 , C07C237/22 , C07C255/60 , C07C271/22 , C07C275/24 , C07C311/08 , C07C311/51 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D213/82 , C07D239/28 , C07D239/34 , C07D239/36 , C07D257/04 , C07D261/18 , C07D263/32 , C07D265/30 , C07D271/06 , C07D295/15 , C07D309/32
摘要: The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式I'化合物; 或其药学上可接受的盐,其中R 1,R 2,R 3,R 5,B 1,X和n如本文所定义。 本发明还涉及制备本发明化合物及其治疗用途的方法。 本发明还提供药理活性剂和药物组合物的组合。
-
-
公开(公告)号:US08263629B2
公开(公告)日:2012-09-11
申请号:US12788794
申请日:2010-05-27
申请人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
发明人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
IPC分类号: A61K31/42 , A61K31/4245 , A61K31/41 , C07D271/04 , C07D271/06 , C07D271/08 , C07D271/10 , C07D263/30 , C07D261/06 , C07D257/02
CPC分类号: A61K31/194 , A61K45/06 , C07C233/47 , C07C233/63 , C07C233/87 , C07C235/52 , C07C235/74 , C07C235/82 , C07C251/12 , C07C257/06 , C07C271/12 , C07C275/16 , C07C311/19 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07D207/34 , C07D209/18 , C07D213/56 , C07D213/81 , C07D213/82 , C07D231/14 , C07D239/28 , C07D261/18 , C07D271/10 , C07D277/64 , C07D285/12 , C07D303/48 , C07D307/68 , C07D309/40 , C07D333/24 , C07D333/40
摘要: The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式I'化合物; 或其药学上可接受的盐,其中R1,R2,R3,X和n如本文所定义。 本发明还涉及制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号:US20110038876A1
公开(公告)日:2011-02-17
申请号:US12601476
申请日:2008-06-17
申请人: Robert Sun , Alan B. Cooper , Yongqi Deng , Tong Wang , Yang Nan , Hugh Y. Zhu , Sobhana Babu Boga , Xiaolei Gao , Joseph M. Kelly , Sunil Paliwal , Hon-Chung Tsui , Ronald J. Doll , Neng-Yang Shih
发明人: Robert Sun , Alan B. Cooper , Yongqi Deng , Tong Wang , Yang Nan , Hugh Y. Zhu , Sobhana Babu Boga , Xiaolei Gao , Joseph M. Kelly , Sunil Paliwal , Hon-Chung Tsui , Ronald J. Doll , Neng-Yang Shih
IPC分类号: A61K31/519 , C07D487/04 , C07D487/08 , A61K31/496 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号: C07D487/04 , C07D519/00
摘要: Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂:[式(1.0)]及其药学上可接受的盐,酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其他取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US20100305145A1
公开(公告)日:2010-12-02
申请号:US12788794
申请日:2010-05-27
申请人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
发明人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
IPC分类号: A61K31/505
CPC分类号: A61K31/194 , A61K45/06 , C07C233/47 , C07C233/63 , C07C233/87 , C07C235/52 , C07C235/74 , C07C235/82 , C07C251/12 , C07C257/06 , C07C271/12 , C07C275/16 , C07C311/19 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07D207/34 , C07D209/18 , C07D213/56 , C07D213/81 , C07D213/82 , C07D231/14 , C07D239/28 , C07D261/18 , C07D271/10 , C07D277/64 , C07D285/12 , C07D303/48 , C07D307/68 , C07D309/40 , C07D333/24 , C07D333/40
摘要: The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式I'化合物; 或其药学上可接受的盐,其中R1,R2,R3,X和n如本文所定义。 本发明还涉及制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
8.
公开(公告)号:US20100305131A1
公开(公告)日:2010-12-02
申请号:US12788766
申请日:2010-05-27
申请人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
发明人: Gary Mark Coppola , Yuki Iwaki , Rajeshri Ganesh Karki , Toshio Kawanami , Gary Michael Ksander , Muneto Mogi , Robert Sun
IPC分类号: A61K31/5375 , C07C235/74 , A61K31/24 , C07D317/40 , A61K31/365 , C07D295/15 , C07C255/60 , C07D239/28 , A61K31/275 , A61K31/505 , C07D239/36 , C07D213/82 , A61K31/44 , C07D309/40 , A61K31/351 , C07D239/42 , C07D213/56 , A61K31/4402 , C07D235/16 , A61K31/4184 , C07D207/16 , A61K31/40 , C07D263/38 , A61K31/421 , C07D277/56 , A61K31/426 , C07D271/113 , A61K31/4245 , C07D257/04 , A61K31/41 , C07D237/24 , A61K31/50 , A61K31/195 , A61P3/04 , A61P9/12 , A61P9/00 , A61P13/12 , A61P15/00 , A61P3/10 , A61P9/10 , A61P29/00 , A61P25/00 , A61P25/08 , A61P25/28 , A61P25/18 , A61P35/02 , A61P25/24 , A61P1/00 , A61P17/02 , A61P27/06
CPC分类号: C07D317/34 , A61K31/197 , A61K31/216 , A61K31/325 , A61K31/351 , A61K31/357 , A61K31/41 , A61K31/421 , A61K31/44 , A61K31/505 , A61K31/5375 , A61K45/00 , A61K45/06 , C07B2200/05 , C07C233/47 , C07C233/49 , C07C233/51 , C07C233/56 , C07C233/63 , C07C235/12 , C07C235/78 , C07C237/16 , C07C237/22 , C07C255/60 , C07C271/22 , C07C275/24 , C07C311/08 , C07C311/51 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D213/82 , C07D239/28 , C07D239/34 , C07D239/36 , C07D257/04 , C07D261/18 , C07D263/32 , C07D265/30 , C07D271/06 , C07D295/15 , C07D309/32
摘要: The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译: 本发明提供式I'化合物; 或其药学上可接受的盐,其中R 1,R 2,R 3,R 5,B 1,X和n如本文所定义。 本发明还涉及制备本发明化合物及其治疗用途的方法。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号:US07807672B2
公开(公告)日:2010-10-05
申请号:US11705709
申请日:2007-02-13
申请人: Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
发明人: Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
IPC分类号: A61K31/506 , A61K31/5377 , A61K31/4025 , A61K31/496 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/06 , C07D417/12
CPC分类号: C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其它取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US20090118284A1
公开(公告)日:2009-05-07
申请号:US11810282
申请日:2007-06-05
申请人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
发明人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
IPC分类号: A61K31/496 , C07D403/14 , C07D413/14 , A61K31/506 , A61P35/00 , A61P35/02 , A61K31/4439 , A61K31/5377 , C07D401/14
CPC分类号: C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐,酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其他取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
-
-
-
-
-
-
-
-